Background: Community-acquired pneumonia (CAP) can lead to pulmonary and systemic inflammation, resulting in impaired gas exchange, sepsis, organ failure, and an increased risk of death. Corticosteroids have excellent anti-inflammatory and immunomodulatory effects that could mitigate some of the inflammation caused ...
Background: There is a shifting paradigm with persuasive evidence favoring a shorter duration of antibiotics for outpatient management of community-acquired pneumonia (CAP) in children. The SAFER and CAP-IT trials found that short-course antibiotic therapy was not inferior to standard duration ...
Background: The standard approach to treating pediatric community-acquired pneumonia (CAP) is a 10-day course of antibiotics. However, two high-quality randomized control trials challenged this standard within the last 12 months. The SAFER Trial and CAP-IT Trial found treatment for CAP in ...
Background/Introduction: The commonly cited duration of antibiotic therapy (7-14 days) for community-acquired pneumonia (CAP) has historically been based on arbitrary timelines extrapolated from a desire to prevent treatment failures and avoid under-treatment rather than evidence-based medicine. Even the original literature on ...
Background: The evidence supporting the use of a 10-day course of high-dose amoxicillin to treat community-acquired pneumonia (CAP) in pediatric patients is weak. In addition, medicine is trending towards shorter courses of antibiotics when clinically appropriate. REBEL EM covered a similar ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
